<!DOCTYPE html>
<!-- saved from url=(0083)https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm -->
<html class="" data-reactroot=""><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./103.亚甲蓝 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app220.us.archive.org';v.server_ms=245;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./103.亚甲蓝 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./103.亚甲蓝 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d10103.htm","20221028212529","https://web.archive.org/","web","/_static/",
	      "1666992329");
</script>
<link rel="stylesheet" type="text/css" href="./103.亚甲蓝 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./103.亚甲蓝 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="亚甲蓝 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028212529/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221028212529im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./103.亚甲蓝 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./103.亚甲蓝 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./103.亚甲蓝 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./103.亚甲蓝 - 搜狗科学百科_files/highlight.min.css"><title>亚甲蓝 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style>
<!--百度统计-->
<script>
   var _hmt = _hmt || [];
   (function() {
      var hm = document.createElement("script");
      hm.src = "https://hm.baidu.com/hm.js?3c7614be3026469d5a60f41ab30b5082";
      var s = document.getElementsByTagName("script")[0]; 
      s.parentNode.insertBefore(hm, s);
      })();
</script>

	<!--百度统计-->
	<script>
		var _hmt = _hmt || [];
		(function() {
			var hm = document.createElement("script");
			hm.src = "https://hm.baidu.com/hm.js?3c7614be3026469d5a60f41ab30b5082";
			var s = document.getElementsByTagName("script")[0]; 
			s.parentNode.insertBefore(hm, s);
			})();
	</script>
</head>
<body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr; height: 311px;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d10103.htm","20221028212529",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('6bd30f4453ed45c7a8f8ad80a0d4d40a') window._gtag.traceId = '6bd30f4453ed45c7a8f8ad80a0d4d40a';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221028212529/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221028212529/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221028212529/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221028212529/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221028212529/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221028212529/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221028212529/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221028212529/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221028212529/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header" class="fix"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value=""><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>亚甲蓝</h1><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="52080200808188173"><div><p>亚甲蓝，也称为3,7-双（二甲氨基）吩噻嗪-5-翁氯化物，是一种药物和染料。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_1" class="kx_ref">[1]</a></sup> 作为一种药物，它主要用于治疗高铁血红蛋白血症。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_1" class="kx_ref">[1]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_2" class="kx_ref">[2]</a></sup> 具体来说，它用于治疗高铁血红蛋白水平高于30%的情况或在已经氧疗的情况下依然有症状发生的情况。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_2" class="kx_ref">[2]</a></sup> 它以前曾用于治疗氰化物中毒和尿路感染，但现在不再推荐使用。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_1" class="kx_ref">[1]</a></sup> 亚甲蓝通常给药方式为静脉注射。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_1" class="kx_ref">[1]</a></sup> </p>
<p>常见的副作用包括头痛、呕吐、精神混乱、气短和高血压。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_1" class="kx_ref">[1]</a></sup> 其他副作用包括血清素综合征、红细胞破裂和过敏反应。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_1" class="kx_ref">[1]</a></sup> 使用经常会导致尿液、汗液和粪便的颜色从蓝色变成绿色。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_2" class="kx_ref">[2]</a></sup> 虽然怀孕期间使用可能会伤害婴儿，但在患有高铁血红蛋白血症情况下不使用可能更危险。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_1" class="kx_ref">[1]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_2" class="kx_ref">[2]</a></sup> 亚甲蓝是噻嗪染料。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_1" class="kx_ref">[1]</a></sup> 它的工作原理是将血红蛋白中的三价铁转化为亚铁。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_2" class="kx_ref">[2]</a></sup> </p>
<p>海因里希·卡罗（Heinrich Caro）于1876年首次制备了亚甲蓝。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_3" class="kx_ref">[3]</a></sup> 它被列入世界卫生组织的基本药物清单，是卫生系统中最有效和最安全的药物。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_4" class="kx_ref">[4]</a></sup> 在美国，一瓶50毫克的药物大约要191.40美元。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_5" class="kx_ref">[5]</a></sup> 在英国，一瓶50毫克的药物要花费国民保健系统大约39.38英镑。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_2" class="kx_ref">[2]</a></sup> </p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col4"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="14994944309592581">医疗用途</a></li><li class="secondary_catalog"><span>1.1 </span><a href="javascript:" data-id="14994944309592581">高铁血红蛋白血症</a></li><li class="secondary_catalog"><span>1.2 </span><a href="javascript:" data-id="14994944309592581">与光结合</a></li><li class="secondary_catalog"><span>1.3 </span><a href="javascript:" data-id="14994944309592581">尿路感染</a></li><li class="secondary_catalog"><span>1.4 </span><a href="javascript:" data-id="14994944309592581">氰化物中毒</a></li><li class="secondary_catalog"><span>1.5 </span><a href="javascript:" data-id="14994944309592581">染料或着色剂</a></li><li class="secondary_catalog"><span>1.6 </span><a href="javascript:" data-id="14994944309592581">安慰剂</a></li><li class="secondary_catalog"><span>1.7 </span><a href="javascript:" data-id="14994944309592581">异环磷酰胺毒性</a></li></ul><ul class="catalog_list col4"><li class="secondary_catalog"><span>1.8 </span><a href="javascript:" data-id="14994944309592581">休克</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="14994944326369805">副作用</a></li><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="14994944326369806">化学</a></li><li class="secondary_catalog"><span>3.1 </span><a href="javascript:" data-id="14994944326369806">制备</a></li><li class="secondary_catalog"><span>3.2 </span><a href="javascript:" data-id="14994944326369806">光吸收特性</a></li><li><span class="order">4</span><a href="javascript:" data-level="1" data-id="14994944326369807">其他用途</a></li><li class="secondary_catalog"><span>4.1 </span><a href="javascript:" data-id="14994944326369807">氧化还原指示剂</a></li><li class="secondary_catalog"><span>4.2 </span><a href="javascript:" data-id="14994944326369807">过氧化物发生器</a></li></ul><ul class="catalog_list col4"><li class="secondary_catalog"><span>4.3 </span><a href="javascript:" data-id="14994944326369807">硫化物分析</a></li><li class="secondary_catalog"><span>4.4 </span><a href="javascript:" data-id="14994944326369807">水测试</a></li><li class="secondary_catalog"><span>4.5 </span><a href="javascript:" data-id="14994944326369807">细集料亚甲蓝值</a></li><li class="secondary_catalog"><span>4.6 </span><a href="javascript:" data-id="14994944326369807">生物染色</a></li><li class="secondary_catalog"><span>4.7 </span><a href="javascript:" data-id="14994944326369807">水产养殖</a></li><li><span class="order">5</span><a href="javascript:" data-level="1" data-id="14994944326369808">历史</a></li><li><span class="order">6</span><a href="javascript:" data-level="1" data-id="14994944326369809">名称</a></li><li><span class="order">7</span><a href="javascript:" data-level="1" data-id="14994944343147014">研究</a></li></ul><ul class="catalog_list col4"><li class="secondary_catalog"><span>7.1 </span><a href="javascript:" data-id="14994944343147014">疟疾</a></li><li class="secondary_catalog"><span>7.2 </span><a href="javascript:" data-id="14994944343147014">阿尔茨海默氏症</a></li><li class="secondary_catalog"><span>7.3 </span><a href="javascript:" data-id="14994944343147014">双相情感障碍</a></li><li class="secondary_catalog"><span>7.4 </span><a href="javascript:" data-id="14994944343147014">病毒</a></li><li><span class="order">8</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_14994944309592581"><h2 class="title">1 医疗用途<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>1.1 <span>高铁血红蛋白血症</span></h3><p></p><p>亚甲蓝被用作治疗高铁血红蛋白血症的药物。病症可能是由于摄入某些药物、毒素或蚕豆引起的。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_6" class="kx_ref">[6]</a></sup> 正常情况下，通过NADH或NADPH依赖的高铁血红蛋白还原酶，高铁血红蛋白被还原为血红蛋白。当大量高铁血红蛋白继发于毒素时，高铁血红蛋白还原酶不堪重负。亚甲蓝作为解毒剂静脉注射时，其本身首先被还原成无色亚甲蓝，然后将血红素从高铁血红蛋白还原成血红蛋白。亚甲蓝可以将高铁血红蛋白的半衰期从几小时缩短到几分钟。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_7" class="kx_ref">[7]</a></sup> 然而，在高剂量下，亚甲蓝实际上会诱发高铁血红蛋白血症，逆转这一途径。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_7" class="kx_ref">[7]</a></sup> </p><p></p><h3>1.2 <span>与光结合</span></h3><p></p><p>亚甲蓝与光结合已被用于治疗耐药斑银屑病。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_8" class="kx_ref">[8]</a></sup> </p><p></p><h3>1.3 <span>尿路感染</span></h3><p></p><p>亚甲蓝是一种经常使用的尿液止痛剂/抗感染剂/解痉剂的成分，称为“Prosed DS”，这是一种药物组合，也含有水杨酸苯酯、苯甲酸、硫酸天仙子胺和次甲基胺(又名六亚甲基四胺，注意：不要与“甲胺”混淆)。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_9" class="kx_ref">[9]</a></sup> </p><p></p><h3>1.4 <span>氰化物中毒</span></h3><p></p><p>由于其还原电位与氧的还原电位相似，并且可以被电子传输链的成分还原，因此大剂量亚甲蓝有时被用作氰化钾中毒的解毒剂。虽然在1926年隆德大学的博·萨赫林（Bo Sahlin）首先证明了这一点，但该方法是1933年由旧金山的马蒂尔达·莫尔登豪尔·布鲁克斯博士（Dr. Matilda Moldenhauer Brooks ）首次成功检验。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_10" class="kx_ref">[10]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_11" class="kx_ref">[11]</a></sup> </p><p></p><h3>1.5 <span>染料或着色剂</span></h3><p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img04.sogoucdn.com/app/a/200698/sogou_science_2329" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title" style="text-align: center;">用亚甲蓝染色的人颊细胞</div>   
        </div> <p></p><p>亚甲蓝在内窥镜息肉切除术中用作盐水或肾上腺素的辅助物，并用于注射到待切除息肉周围的粘膜下层。这样可以在息肉切除后识别粘膜下层组织平面，这有助于确定是否需要切除更多组织，或者是否存在穿孔的高风险。亚甲蓝也被用作染色内窥镜检查中的染料，并被喷洒到胃肠道粘膜上，以识别发育异常或癌前病变。通过静脉注射的亚甲蓝很容易释放到尿液中，因此可用于检查泌尿道是否有渗漏或瘘管。</p><p>在诸如前哨淋巴结切除手术中，亚甲蓝可用于目视追踪受试组织的淋巴引流。同样，在整形外科手术中，亚甲蓝被添加到骨水泥中，用于区分天然骨和骨水泥。此外，亚甲蓝能够加速骨水泥的硬化速度，提高骨水泥的有效应用速度。亚甲蓝在许多医疗器械中被用作可视化/定向的辅助工具，包括外科手术密封膜，组织贴片。在瘘管和藏毛窦中，它被用来识别需要完全切除的管道。</p><p>当亚甲蓝被“多色化”(在溶液中氧化或通过真菌代谢而达到“成熟”转态，<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_12" class="kx_ref">[12]</a></sup> 正如罗曼诺夫斯基（D.L.Romanowsky）博士在19世纪90年代的论文中所指出那样），它被连续脱甲基并形成所有的三甲基、二甲基、单甲基和非甲基中间体，分别对应天青A、天青B、天青C及硫堇。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_13" class="kx_ref">[13]</a></sup> 这是罗曼诺夫斯基-吉姆萨效应光谱中嗜碱性部分的基础。如果只使用合成的天青B和曙红Y，它可以作为标准的吉姆萨染色剂；但是，如果没有亚甲蓝，正常的中性粒细胞粒往往会过度染色，看起来像有毒细胞粒。另一方面，如果使用亚甲蓝，可能有助于呈现中性粒细胞颗粒的正常外观，也能增强核仁和多色性红细胞（网织红细胞）的染色。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_14" class="kx_ref">[14]</a></sup> </p><p>亚甲蓝的一个传统应用是对神经纤维进行活体或超活体染色，这种效果是保罗·埃尔利希（Paul Ehrlich ）在1887年首次描述的。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_15" class="kx_ref">[15]</a></sup> 将稀释的染料溶液注射到组织中，或者涂在新鲜去除的小片上。选择性蓝色随着在空气（氧气）中暴露而显影，可以通过将染色样品浸入钼酸铵水溶液中固定下来。活性亚甲蓝以前常用于检查肌肉、皮肤和内脏的神经分布。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_16" class="kx_ref">[16]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_17" class="kx_ref">[17]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_18" class="kx_ref">[18]</a></sup> 选择性染料吸收的机制还不完全清楚；哇巴因是一种抑制细胞膜钠/钾三磷酸腺苷酶（Na/K-ATPase）的药物，其可以抑制皮肤神经纤维的活体染色。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_19" class="kx_ref">[19]</a></sup> </p><p></p><h3>1.6 <span>安慰剂</span></h3><p></p><p>亚甲蓝被用作安慰剂；医生会告诉病人，希望他们的尿液变色，并把这看作是他们病情好转的标志。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_20" class="kx_ref">[20]</a></sup> 不利的一面是，该副作用使得亚甲蓝在传统安慰剂对照临床研究中难以测试。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_21" class="kx_ref">[21]</a></sup> </p><p></p><h3>1.7 <span>异环磷酰胺毒性</span></h3><p></p><p>亚甲蓝的另一个用途是治疗异环磷酰胺的神经毒性。亚甲蓝在1994年首次被报道用于异环磷酰胺神经精神毒性的治疗和预防。异环磷酰胺的有毒代谢物氯乙醛（CAA）能破坏线粒体呼吸链，导致烟酰胺腺嘌呤二核苷酸氢（NADH）的积累。亚甲蓝作为另一种替代电子受体，逆转NADH对肝脏糖异生的抑制作用，同时还能抑制氯乙胺转化为氯乙醛，并抑制多种胺氧化酶活性，防止CAA的形成。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_22" class="kx_ref">[22]</a></sup> 治疗异环磷酰胺神经毒性的亚甲蓝剂量的变化取决于它在异环磷酰胺输注中作为佐剂的用途，而不是用于逆转在异环磷酰胺输注完成后出现的精神症状。报告建议，每天最多给药亚甲蓝六剂，可在10分钟至几天内改善症状。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_23" class="kx_ref">[23]</a></sup> 另外，有人建议在异环磷酰胺治疗期间，对有异环磷酰胺神经精神毒性病史的人，每隔6小时静脉注射亚甲蓝进行预防。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_24" class="kx_ref">[24]</a></sup> 推荐在使用异环磷酰胺开始的前一天预防性施用亚甲蓝，并在异环磷酰胺化疗期间每天施用三次，以降低异环磷酰胺神经毒性的发生可能性。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_25" class="kx_ref">[25]</a></sup> </p><p></p><h3>1.8 <span>休克</span></h3><p></p><p>它也被用于感染性休克和过敏反应。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_26" class="kx_ref">[26]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_27" class="kx_ref">[27]</a></sup> </p><p>亚甲蓝会持续增加血管麻痹综合征（再分布性休克）患者的血压，但并未显示出可改善向组织输送氧气的效率或降低死亡率。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_28" class="kx_ref">[28]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_29" class="kx_ref">[29]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_30" class="kx_ref">[30]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_31" class="kx_ref">[31]</a></sup> </p></div></div><div id="par_14994944326369805"><h2 class="title">2 副作用<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>
 </p><table class="wikitable">
  <tbody>
   <tr>
    <th>心血管</th>
    <th>中枢神经系统</th>
    <th>皮肤</th>
    <th>胃肠</th>
    <th>泌尿生殖系统</th>
    <th>血液</th>
   </tr>
   <tr>
    <td>• 高血压<br>• 心前区痛</td>
    <td>• 头晕<br>• 精神混乱<br>• 头痛<br>• 发烧</td>
    <td>• 皮肤染色<br>• 注射部位坏死</td>
    <td>• 粪便变色<br>• 恶心<br>• 呕吐<br>• 腹痛</td>
    <td>• 尿液变色（剂量超过80克）<br>• 膀胱刺激</td>
    <td>• 贫血</td>
   </tr>
  </tbody>
 </table><p></p><p><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_32" class="kx_ref">[32]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_33" class="kx_ref">[33]</a></sup> </p><p>亚甲蓝是单胺氧化酶抑制剂（MAOI），<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_34" class="kx_ref">[34]</a></sup> 当以超过5毫克/千克的剂量静脉注射时，如果其与任何选择性血清素再摄取抑制剂（SSRIs）或其他血清素再摄取抑制剂（例如度洛西汀、西布曲明、文拉法辛、氯米帕明、丙咪嗪）联用，可能会导致严重血清素毒性或血清素综合征。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_35" class="kx_ref">[35]</a></sup> </p><p>它会引发G6PD（favism）酶缺乏症携带者的溶血性贫血。</p></div></div><div id="par_14994944326369806"><h2 class="title">3 化学<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>亚甲蓝是吩噻嗪的缩甲醛衍生物。这是一种深绿色粉末，能在水中产生蓝色溶液。其水合物中，每单位亚甲蓝含有3分子水。亚甲基蓝在25℃（77℉）的水中的pH为3（10g/l）。</p><p></p><h3>3.1 <span>制备</span></h3><p></p><p>该化合物通过在硫代硫酸钠存在下氧化二甲基-4-苯二胺制备：<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_36" class="kx_ref">[36]</a></sup> </p><p>
 </p><dl>
  <dd>
   <div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img03.sogoucdn.com/app/a/200698/sogou_science_2333" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title" style="text-align: center;"></div>   
        </div> 
  </dd>
 </dl><p></p><p></p><h3>3.2 <span>光吸收特性</span></h3><p></p><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img03.sogoucdn.com/app/a/200698/sogou_science_4388" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title">亚甲基蓝的吸收光谱，以摩尔消光系数（以10为底的对数）表示。在该数据集中，当665 nm的光通过1 cm的10 mmol亚甲基蓝溶液时，观察到峰值吸光度为1.7（即98%的透射光被吸收）。</div>   
        </div> <p></p><p>最大吸收波段大约为670纳米。吸收的具体细节取决于许多因素，包括质子化、对其他材料的吸附和异染性——这是一种根据浓度和其他相互作用形成二聚体和高阶聚集体：<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_37" class="kx_ref">[37]</a></sup> </p><p>
 </p><table class="wikitable">
  <tbody>
   <tr>
    <th>种类</th>
    <th>吸收峰</th>
    <th>消光系数 (dm<sup>3</sup>/mole·cm)</th>
   </tr>
   <tr>
    <td>MB<sup>+</sup>(溶液)</td>
    <td>664</td>
    <td>95000</td>
   </tr>
   <tr>
    <td>MBH<sub>2</sub><sup>+</sup> (溶液)</td>
    <td>741</td>
    <td>76000</td>
   </tr>
   <tr>
    <td>(MB<sup>+</sup>)<sub>2</sub> (溶液)</td>
    <td>605</td>
    <td>132000</td>
   </tr>
   <tr>
    <td>(MB<sup>+</sup>)<sub>3</sub> (溶液)</td>
    <td>580</td>
    <td>110000</td>
   </tr>
   <tr>
    <td>MB<sup>+</sup> (吸附在粘土上)</td>
    <td>673</td>
    <td>116000</td>
   </tr>
   <tr>
    <td>MBH<sub>2</sub><sup>+</sup> (吸附在粘土上)</td>
    <td>763</td>
    <td>86000</td>
   </tr>
   <tr>
    <td>(MB<sup>+</sup>)<sub>2</sub> (吸附在粘土上)</td>
    <td>596</td>
    <td>80000</td>
   </tr>
   <tr>
    <td>(MB<sup>+</sup>)<sub>3</sub> (吸附在粘土上)</td>
    <td>570</td>
    <td>114000</td>
   </tr>
  </tbody>
 </table><p></p></div></div><div id="par_14994944326369807"><h2 class="title">4 其他用途<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><div class="text_img ed_imgfloat_right">
            <a class="ed_image_link lazyLoad" data-src="https://img02.sogoucdn.com/app/a/200698/sogou_science_4389" data-bigsrc="" title="点击查看大图" href="javascript:" data-observer="true"></a>
            <div class="text_img_title" style="text-align: center;">装有亚甲基蓝溶液的容量瓶</div>   
        </div> <p></p><p></p><h3>4.1 <span>氧化还原指示剂</span></h3><p></p><p>亚甲蓝被广泛地用作分析化学中的氧化还原指示剂。在氧化环境中，这种物质的溶液是蓝色的，但是如果暴露在还原剂中，溶液会变成无色的。氧化还原性质可以在普通化学的化学动力学的经典演示“蓝瓶”实验中看到。通常，溶液由葡萄糖（右旋糖）、亚甲蓝和氢氧化钠组成。摇动瓶子时，氧气氧化亚甲蓝，溶液变成蓝色。葡萄糖会逐渐将亚甲蓝还原成无色的还原型。因此，当溶解的葡萄糖被完全消耗时，溶液将再次变成蓝色。氧化还原中点电位E0’为+0.011毫伏。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_38" class="kx_ref">[38]</a></sup> </p><p></p><h3>4.2 <span>过氧化物发生器</span></h3><p></p><p>亚甲蓝也是一种光敏剂，用于在暴露于氧气和光线时产生单线态氧。 它被用于通过狄尔斯-阿尔德（Diels-Alder）反应制备有机过氧化物，该反应在正常大气中三线态氧环境下是自旋禁止的。</p><p></p><h3>4.3 <span>硫化物分析</span></h3><p></p><p>硫化氢与二甲基对苯二胺和铁（III）在pH0.4–0.7条件下反应后形成亚甲蓝，通过分光光度法测定硫化物浓度范围为0.020至1.50mg/l（20 ppb至1.5 ppm）。该测试非常灵敏，试剂与溶解的H<sub>2</sub>S接触时产生的蓝色稳定60 分钟。即用型试剂盒如光谱定量硫化物测试方便了例行分析。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_39" class="kx_ref">[39]</a></sup> 亚甲蓝硫化物试验是土壤微生物学中常用的一种快速检测水中硫酸盐还原菌（SRB）代谢活性的简便方法。应该注意到在该试验中，亚甲蓝是反应的产物，而不是试剂。</p><p>向含硫化物的溶液中加入强还原剂，如抗坏血酸，有时用于防止硫化物在大气氧中氧化。尽管用离子选择性电极测定硫化物也确实是一个很好的预防措施，但如果新形成的亚甲基蓝也被还原，则可能会妨碍蓝色的形成，如上文氧化还原指示剂一节所述。</p><p></p><h3>4.4 <span>水测试</span></h3><p></p><p>在含有氯仿的酸化亚甲蓝水溶液中的显色反应可以检测水样中的阴离子表面活性剂。这种试验被称为MBAS试验（亚甲蓝活性物质试验）。</p><p>然而，MBAS分析不能区分特定的表面活性剂。阴离子表面活性剂的一些实例是羧酸盐、磷酸盐、硫酸盐和磺酸盐。</p><p></p><h3>4.5 <span>细集料亚甲蓝值</span></h3><p></p><p>亚甲蓝值反映了集料样品中粘土矿物的数量。亚甲蓝溶液被连续加入到正在水中搅拌的细集料中。可用滤纸上的染色试验来检查游离染料溶液的存在。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_40" class="kx_ref">[40]</a></sup> </p><p></p><h3>4.6 <span>生物染色</span></h3><p></p><p>在生物学中，亚甲蓝被用作许多不同染色程序的染料，例如Wright染色和Jenner染色。由于它是一种临时染色技术，亚甲蓝也可用于在显微镜下或凝胶中检查核糖核酸（RNA）或脱氧核糖核酸（DNA）：例如，亚甲蓝溶液可用于在northern印迹中对杂交膜上的核糖核酸进行染色，以验证核酸的存在量。虽然亚甲蓝不如溴化乙锭敏感，但毒性较低，并且不嵌入核酸链，因此避免了对杂交膜上保留的核酸或杂交过程本身的干扰。</p><p>它也可以用作确定真核细胞如酵母存活或者死亡的指示物。亚甲蓝在活细胞中被还原，使其避免染色。然而死细胞不能还原被氧化的亚甲蓝，细胞被染成蓝色。亚甲蓝会干扰酵母的呼吸，因为它会吸收在此过程中产生的氢离子。</p><p></p><h3>4.7 <span>水产养殖</span></h3><p></p><p>亚甲蓝被水产养殖从业者和热带鱼爱好者用作真菌感染的治疗手段。虽然孔雀石绿和甲醛的组合对寄生的原生动物多子小瓜虫（ich）更有效，但亚甲蓝也能有效治疗感染ich的鱼。它通常用于保护新产的鱼卵免受真菌或细菌的感染。当爱好者想要人工孵化鱼卵时，这很有用。亚甲蓝在作为“药浴”的一部分用于治疗氨、亚硝酸盐和氰化物中毒以及作为“第一反应”用于受伤或患病鱼的局部和内部治疗时也非常有效。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_41" class="kx_ref">[41]</a></sup> </p></div></div><div id="par_14994944326369808"><h2 class="title">5 历史<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>亚甲蓝被描述为“第一种用于医药的全合成药物”。亚甲蓝最初是由德国化学家海因里希·卡罗（Heinrich Caro）在1876年制备的。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_42" class="kx_ref">[42]</a></sup> </p><p>保罗·古特曼（Paul Guttmann）和保罗·埃尔利希（Paul Ehrlich）在1891年率先将它用于治疗疟疾。在第一次世界大战前的这段时间里，像埃利希这样的研究人员认为，药物和染料的作用方式是一样的，优先染色病原体，并可能对它们造成伤害。各种药物的作用方式实际上是改变病原体的细胞膜，所以这个理论虽然远未完成，但部分正确。亚甲蓝在第二次世界大战中被继续使用，然而士兵们并不太喜欢它，他们说：“即使在厕所，我们也看到；我们撒尿时也看到，海军蓝。” 最近恢复了这种药物的抗疟药使用。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_43" class="kx_ref">[43]</a></sup> 马蒂尔达·布鲁克斯（Matilda Brooks）在1933年发现它是一氧化碳中毒和氰化物中毒的解毒剂。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_44" class="kx_ref">[44]</a></sup> </p><p>蓝色尿液用于监测精神病患者对药物治疗方案的依从性。从19世纪90年代至今，这引起了人们对这种药物的抗抑郁和其他精神作用的兴趣。它成为导致氯丙嗪被发现研究中的先导化合物。 </p></div></div><div id="par_14994944326369809"><h2 class="title">6 名称<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>亚甲蓝的国际非专利名称（INN）是氯化亚甲基硫堇。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_45" class="kx_ref">[45]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_46" class="kx_ref">[46]</a></sup> </p></div></div><div id="par_14994944343147014"><h2 class="title">7 研究<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>7.1 <span>疟疾</span></h3><p></p><p>亚甲蓝大约在1891年被保罗·埃尔利希确定为一种可能的疟疾治疗方法。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_47" class="kx_ref">[47]</a></sup> 在太平洋战争期间，它作为抗疟疾药在热带地区消失了，因为美国和盟军士兵不喜欢它的两个显著但可逆的副作用：尿液变成蓝色或绿色，巩膜（眼白）变成蓝色。最近人们对其作为抗疟疾药物的兴趣有所恢复，<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_48" class="kx_ref">[48]</a></sup> 特别是由于其价格低廉。一些临床试验正在进行中，试图找到一种合适的药物组合。根据对非洲儿童的研究，它似乎对疟疾有疗效，但是将亚甲蓝和氯喹结合的尝试令人失望。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_48" class="kx_ref">[48]</a></sup> </p><p></p><h3>7.2 <span>阿尔茨海默氏症</span></h3><p></p><p>亚甲蓝衍生物-LMTM（TauRx0237或LMT-X）的3期临床试验数据未能显示出对轻度至中度阿尔茨海默病患者的认知或功能衰退有任何益处。药物和安慰剂对疾病进程的作用是几乎相同的。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_49" class="kx_ref">[49]</a></sup><sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_50" class="kx_ref">[50]</a></sup> </p><p></p><h3>7.3 <span>双相情感障碍</span></h3><p></p><p>亚甲蓝已被研究作为治疗双相情感障碍的辅助药物。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_51" class="kx_ref">[51]</a></sup> </p><p></p><h3>7.4 <span>病毒</span></h3><p></p><p>亚甲蓝在与艾滋病相关的卡波西肉瘤、<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_52" class="kx_ref">[52]</a></sup> 西尼罗河病毒、<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_53" class="kx_ref">[53]</a></sup> 灭活金菌黄色葡萄球<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_54" class="kx_ref">[54]</a></sup> 和HIV-1中被研究过。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_55" class="kx_ref">[55]</a></sup> 吩噻嗪染料和光在70多年前就被认为具有杀病毒特性。<sup><a href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/d10103.htm#quote_56" class="kx_ref">[56]</a></sup> </p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Methylene Blue". The American Society of Health-System Pharmacists. Archived from the original on 10 May 2017. Retrieved 8 January 2017..</span></p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 34. ISBN 9780857111562..</span></p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ahmad, Iqbal; Aqil, Farrukh (2008). New Strategies Combating Bacterial Infection (in 英语). John Wiley &amp; Sons. p. 91. ISBN 9783527622948. Archived from the original on 2017-09-18..</span></p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016..</span></p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Provayblue Prices, Coupons &amp; Patient Assistance Programs - Drugs.com". www.drugs.com. Archived from the original on 16 January 2017. Retrieved 12 January 2017..</span></p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Manual of Clinical Hematology Archived 2017-09-18 at the Wayback Machine, Joseph Mazza.</span></p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Brent J. (2005). Critical care toxicology: diagnosis and management of the critically poisoned patient. Elsevier Health Sciences..</span></p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Salah M.; Samy N.; Fadel M. (January 2009). "Methylene blue mediated photodynamic therapy for resistant plaque psoriasis". J. Drugs Dermatol. 8 (1): 42–9. PMID 19180895..</span></p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Prosed DS (Methenamine, Salicylate, Methylene Blue, Benzoic Acid Atropine and Hyoscyamine) Drug Information: Description, User Reviews, Drug Side Effects, Interactions - Prescribing Information at RxList". RxList. Archived from the original on 2011-11-02..</span></p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Matilda Moldenhauer Brooks (1936). "Methylene blue as an antidote for cyanide and carbon monoxide poisoning". The Scientific Monthly. 43 (6): 585–586. Bibcode:1936SciMo..43..585M. JSTOR 16280..</span></p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hanzlik, P. J. (4 February 1933). "Methylene Blue As Antidote for Cyanide Poisoning". JAMA. 100 (5): 357. doi:10.1001/jama.1933.02740050053028..</span></p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dako Education Guide - Special Stains and H &amp; E " second edition Chapter 19: On Chemical Reactions and Staining Mechanisms by John A. Kiernan, Subsection What is Giemsa's stain and how does it color blood cells, bacteria and chromosomes? p172 Archived 2012-05-13 at the Wayback Machine.</span></p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Wilson TM (1907). "ON THE CHEMISTRY AND STAINING PROPERTIES OF CERTAIN DERIVATIVES OF THE METHYLENE BLUE GROUP WHEN COMBINED WITH EOSIN". J Exp Med. 9 (6): 645–70. doi:10.1084/jem.9.6.645. PMC 2124692. PMID 19867116..</span></p></li><li id="quote_14"><span class="references-num">[14]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dacie and Lewis Practical Haematology 10th ed, p61.</span></p></li><li id="quote_15"><span class="references-num">[15]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ehrlich, P. (1887) Biol. Centralblatt 6: 214, cited from Baker JR (1958) Principles of Biological Microtechnique (Reprinted 1970, with corrections). Methuen, London..</span></p></li><li id="quote_16"><span class="references-num">[16]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Wilson JG (1910) Intra vitam staining with methylene blue. Anatomical Record 4: 267-277..</span></p></li><li id="quote_17"><span class="references-num">[17]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Schabadasch A (1930) Untersuchungen zur Methodik der Methylenblaufarbung des vegetativen Nervensystems. Zeitschrift für Zellforschung 10: 221-243..</span></p></li><li id="quote_18"><span class="references-num">[18]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Zacks Zacks SI (1973) The Motor Endplate, 2nd ed. Huntington, NY: Krieger.</span></p></li><li id="quote_19"><span class="references-num">[19]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kiernan JA (1974) Effects of metabolic inhibitors on vital staining with methylene blue. Histochemistry 40: 51-57..</span></p></li><li id="quote_20"><span class="references-num">[20]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Novella Steve. "The ethics of deception in medicine". Science Based Medicine. Archived from the original on 2008-01-29. Retrieved 2008-01-24..</span></p></li><li id="quote_21"><span class="references-num">[21]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Methylene blue for cognitive dysfunction in bipolar disorder". United States National Library of Medicine. September 20, 2005. Archived from the original on January 15, 2009. Retrieved 2009-02-15..</span></p></li><li id="quote_22"><span class="references-num">[22]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Alici-Evcimen Y.; Breitbart W.S. (October 2007). "Ifosfamide neuropsychiatric toxicity in patients with cancer". Psychooncology. 16 (10): 956–960. doi:10.1002/pon.1161. PMID 17278152..</span></p></li><li id="quote_23"><span class="references-num">[23]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Patel P.N. (2006). "Methylene blue for management of ifosfamide induced encephalopathy". Annals of Pharmacotherapy. 40 (2): 266–303. doi:10.1345/aph.1G114. PMID 16391008..</span></p></li><li id="quote_24"><span class="references-num">[24]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Dufour C., Grill J., Sabouraud P., et al. (February 2006). "Ifosfamide induced encephalopathy: 15 observations". Arch. Pediatr. (in French). 13 (2): 140–145. doi:10.1016/j.arcped.2005.10.021. PMID 16364615.CS1 maint: Unrecognized language (link).</span></p></li><li id="quote_25"><span class="references-num">[25]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Aeschlimann T.; Cerny, T; Küpfer, A (1996). "Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue". Drug Metab. Dispos. 24 (12): 1336–1339. PMID 8971139..</span></p></li><li id="quote_26"><span class="references-num">[26]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Jang, DH; Nelson, LS; Hoffman, RS (September 2013). "Methylene blue for distributive shock: a potential new use of an old antidote". Journal of Medical Toxicology. 9 (3): 242–9. doi:10.1007/s13181-013-0298-7. PMID 23580172..</span></p></li><li id="quote_27"><span class="references-num">[27]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Paciullo, CA; McMahon Horner, D; Hatton, KW; Flynn, JD (July 2010). "Methylene blue for the treatment of septic shock". Pharmacotherapy. 30 (7): 702–15. doi:10.1592/phco.30.7.702. PMID 20575634..</span></p></li><li id="quote_28"><span class="references-num">[28]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Hosseinian L, Weiner M, Levin MA, Fischer GW (January 2016). "Methylene Blue: Magic Bullet for Vasoplegia?". Anesth. Analg. 122 (1): 194–201. doi:10.1213/ANE.0000000000001045. PMID 26678471..</span></p></li><li id="quote_29"><span class="references-num">[29]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, Boullon FJ (February 2004). "Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery". Ann Thorac Surg. 77 (2): 496–9. doi:10.1016/S0003-4975(03)01510-8. PMID 14759425..</span></p></li><li id="quote_30"><span class="references-num">[30]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"BestBets: Is Methylene Blue of benefit in treating adult patients who develop vasoplegic syndrome during Cardiac Surgery". Archived from the original on 2014-07-28..</span></p></li><li id="quote_31"><span class="references-num">[31]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Stawicki SP, Sims C, Sarani B, Grossman MD, Gracias VH (May 2008). "Methylene blue and vasoplegia: who, when, and how?". Mini Rev Med Chem. 8 (5): 472–90. doi:10.2174/138955708784223477. PMID 18473936..</span></p></li><li id="quote_32"><span class="references-num">[32]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Mokhlesi B.; Leikin J.B.; Murray P.; Corbridge T.C. (March 2003). "Adult toxicology in critical care: Part II: specific poisonings". Chest. 123 (3): 897–922. doi:10.1378/chest.123.3.897. PMID 12628894..</span></p></li><li id="quote_33"><span class="references-num">[33]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Harvey J.W.; Keitt A.S. (May 1983). "Studies of the efficacy and potential hazards of methylene blue therapy in aniline-induced methaemoglobinaemia". Br. J. Haematol. 54 (1): 29–41. doi:10.1111/j.1365-2141.1983.tb02064.x. PMID 6849836..</span></p></li><li id="quote_34"><span class="references-num">[34]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ramsay RR; Dunford, C.; Gillman, C.K. (August 2007). "Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction". Br J Pharmacol. 152 (6): 946–951. doi:10.1038/sj.bjp.0707430. PMC 2078225. PMID 17721552..</span></p></li><li id="quote_35"><span class="references-num">[35]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Gillman P.K. (October 2006). "Methylene blue implicated in potentially fatal serotonin toxicity". Anaesthesia. 61 (10): 1013–4. doi:10.1111/j.1365-2044.2006.04808.x. PMID 16978328..</span></p></li><li id="quote_36"><span class="references-num">[36]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Horst Berneth (2012). "Azine Dyes". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a03_213.pub3. ISBN 978-3527306732..</span></p></li><li id="quote_37"><span class="references-num">[37]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">J. Cenens; R. A. Schoonheydt (1988). "Visible spectroscopy of methylene blue on hectorite, laponite B, and barasym in aqueous suspension" (PDF). Clay and Clay Minerals. 36 (3): 214–224. Bibcode:1988CCM....36..214C. doi:10.1346/ccmn.1988.0360302. Archived (PDF) from the original on 2011-06-12..</span></p></li><li id="quote_38"><span class="references-num">[38]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">HEWITT, LF. "Oxidation-Reduction Potentials in Bacteriology and Biochemistry." Oxidation-Reduction Potentials in Bacteriology and Biochemistry. Edn 6 (1950)..</span></p></li><li id="quote_39"><span class="references-num">[39]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Analytik und Probenvorbereitung". Archived from the original on 2007-03-15..</span></p></li><li id="quote_40"><span class="references-num">[40]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Construction Standard CS3:2013 – Aggregates for Concrete Archived 2014-06-02 at the Wayback Machine.</span></p></li><li id="quote_41"><span class="references-num">[41]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">[1] Archived 2016-01-10 at the Wayback Machine.</span></p></li><li id="quote_42"><span class="references-num">[42]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Badische Anilin- und Sodafabrik [BASF] (Mannheim, Germany), "Verfahren zur Darstellung blauer Farbstoffe aus Dimethylanilin und anderen tertiaren aromatischen Monaminen" (Method for preparation of blue dyes from dimethylaniline and other tertiary aromatic monoamines), Deutsches Reich Patent no. 1886 (December 15, 1877). Available on-line at: P. Friedlaender, Fortschritte der Theerfarbenfabrikation und verwandter Industriezweige (Progress of the manufacture of coal-tar dyes and related branches of industry), volume 1 (Berlin, Germany: Julius Springer, 1888), pages 247-249. Archived 2015-03-21 at the Wayback Machine.</span></p></li><li id="quote_43"><span class="references-num">[43]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Coulibaly, Boubacar; Zoungrana, Augustin; Mockenhaupt, Frank P.; Schirmer, R. Heiner; Klose, Christina; Mansmann, Ulrich; Meissner, Peter E.; Müller, Olaf (2009). "PLOS ONE". PLoS ONE. 4 (5): e5318. Bibcode:2009PLoSO...4.5318C. doi:10.1371/journal.pone.0005318. PMC 2673582. PMID 19415120..</span></p></li><li id="quote_44"><span class="references-num">[44]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Brooks, Matilda Moldenhauer (1933). "Methylene Blue As Antidote for Cyanide and Carbon Monoxide Poisoning". JAMA. 100: 59. doi:10.1001/jama.1933.02740010061028..</span></p></li><li id="quote_45"><span class="references-num">[45]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Adams V.; Marley J.; McCarroll C. (November 2007). "Prilocaine induced methaemoglobinaemia in a medically compromised patient. Was this an inevitable consequence of the dose administered?". Br. Dent. J. 203 (10): 585–7. doi:10.1038/bdj.2007.1045. PMID 18037845..</span></p></li><li id="quote_46"><span class="references-num">[46]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Linz A.J.; Greenham R.K.; Fallon L.F. (May 2006). "Methemoglobinemia: an industrial outbreak among rubber molding workers". J. Occup. Environ. Med. 48 (5): 523–8. doi:10.1097/01.jom.0000201815.32098.99. PMID 16688009..</span></p></li><li id="quote_47"><span class="references-num">[47]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Guttmann, P. and Ehrlich. P. (1891) "Über die Wirkung des Methylenblau bei Malaria" Archived 2017-02-17 at the Wayback Machine (On the effect of methylene blue on malaria), Berliner Klinische Wochenschrift, 28 : 953-956..</span></p></li><li id="quote_48"><span class="references-num">[48]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Schirmer H.; Coulibaly B.; Stich A.; et al. (2003). "Methylene blue as an antimalarial agent—past and future". Redox Rep. 8 (5): 272–276. doi:10.1179/135100003225002899. PMID 14962363..</span></p></li><li id="quote_49"><span class="references-num">[49]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Tau Drug Flops in Study"..</span></p></li><li id="quote_50"><span class="references-num">[50]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period"..</span></p></li><li id="quote_51"><span class="references-num">[51]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Alda, Martin; McKinnon, Margaret; Blagdon, Ryan; Garnham, Julie; MacLellan, Susan; O'Donovan, Claire; Hajek, Tomas; Nair, Cynthia; Dursun, Serdar (2017-01-01). "Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study". The British Journal of Psychiatry. 210 (1): 54–60. doi:10.1192/bjp.bp.115.173930. ISSN 1472-1465. PMID 27284082..</span></p></li><li id="quote_52"><span class="references-num">[52]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Tardivo J.P.; Del Giglio A.; Paschoal L.H.; Baptista M.S. (August 2006). "New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma". Photomedical Laser Surg. 24 (4): 528–31. doi:10.1089/pho.2006.24.528. PMID 16942436..</span></p></li><li id="quote_53"><span class="references-num">[53]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Papin J.F.; Floyd R.A.; Dittmer D.P. (November 2005). "Methylene blue photoinactivation abolishes West Nile virus infectivity in vivo". Antiviral Res. 68 (2): 84–7. doi:10.1016/j.antiviral.2005.07.001. PMID 16118025..</span></p></li><li id="quote_54"><span class="references-num">[54]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Zolfaghari P.S.; Packer S.; Singer M.; Nair S.P.; Bennett J.; Street C.; Wilson M. (2009). "In vivo killing of Staphylococcus aureus using a light-activated antimicrobial agent". BMC Microbiol. 9: 27. doi:10.1186/1471-2180-9-27. PMC 2642833. PMID 19193212..</span></p></li><li id="quote_55"><span class="references-num">[55]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Floyd R.A.; Schneider J.E.; Dittmer D.P. (March 2004). "Methylene blue photoinactivation of RNA viruses". Antiviral Res. 61 (3): 141–51. doi:10.1016/j.antiviral.2003.11.004. PMID 15168794..</span></p></li><li id="quote_56"><span class="references-num">[56]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Wagner S.J.; Skripchenko A.; Robinette D.; Mallory D.A.; Hirayama J.; Cincotta L.; Foley J. (2000). "The use of dimethylmethylene blue for virus photoinactivation of red cell suspensions". Dev. Biol. (Basel). 102: 125–9. PMID 10794099..</span></p></li></ul></div><div class="read-num">阅读 <!-- -->5505</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221028212529/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221028212529/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221028212529/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221028212529/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"10103","versionId":"52080200808188164","title":"亚甲蓝","subtitle":"","abstracts":{"paragraphId":"52080200808188173","title":"摘要","versionId":"52080200808188165","lemmaId":10103,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598338218,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p>亚甲蓝，也称为3,7-双（二甲氨基）吩噻嗪-5-翁氯化物，是一种药物和染料。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> 作为一种药物，它主要用于治疗高铁血红蛋白血症。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup><sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 具体来说，它用于治疗高铁血红蛋白水平高于30%的情况或在已经氧疗的情况下依然有症状发生的情况。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 它以前曾用于治疗氰化物中毒和尿路感染，但现在不再推荐使用。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> 亚甲蓝通常给药方式为静脉注射。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> </p>\n<p>常见的副作用包括头痛、呕吐、精神混乱、气短和高血压。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> 其他副作用包括血清素综合征、红细胞破裂和过敏反应。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> 使用经常会导致尿液、汗液和粪便的颜色从蓝色变成绿色。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 虽然怀孕期间使用可能会伤害婴儿，但在患有高铁血红蛋白血症情况下不使用可能更危险。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup><sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> 亚甲蓝是噻嗪染料。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup> 它的工作原理是将血红蛋白中的三价铁转化为亚铁。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> </p>\n<p>海因里希·卡罗（Heinrich Caro）于1876年首次制备了亚甲蓝。<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup> 它被列入世界卫生组织的基本药物清单，是卫生系统中最有效和最安全的药物。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> 在美国，一瓶50毫克的药物大约要191.40美元。<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup> 在英国，一瓶50毫克的药物要花费国民保健系统大约39.38英镑。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"0","title":"","versionId":"0","lemmaId":0,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":0,"comment":null,"dependVersionId":0,"contentType":0,"content":"","pics":null,"card":null,"references":null,"versionCount":0},"categories":[{"id":3,"name":"化学","parents":[]}],"creator":{"uid":10145103,"name":"柚子otto","pic":"https://web.archive.org/web/20221028212529/https://img02.sogoucdn.com/app/a/200698/1152_1152_1864088_20200427232849-1518843971.png","introduction":"","educations":[{"schoolName":"中国地质大学（北京）","major":"","degree":"本科","universityId":22,"universityLogo":"https://web.archive.org/web/20221028212529/https://img01.sogoucdn.com/app/a/200943/d3465c1c-6011-11e9-b353-fc4dd4f70029","majorLevel1":"理学","majorLevel2":"地理学","majorLevel3":"地图学与地理信息系统","majorLevel1Id":1,"majorLevel2Id":103,"majorLevel3Id":109,"state":"毕业","lab":"","researchField":""}],"jobs":[{"company":"搜狗","title":"产品经理"}],"works":null,"educationBrief":"中国地质大学（北京）","jobBrief":"产品经理","role":0,"roleName":null,"title":"中国地质大学（北京） · 地理学本科","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":139,"partnerIdCreateTime":1595844881,"partnerIdPoped":true},"createTime":1571038203,"editor":{"uid":81910391,"name":"是福不是祸","pic":"https://web.archive.org/web/20221028212529/https://cache.soso.com/qlogo/g?b=oidb&k=6iaUd8ybMyWyTRyUPWibRsLg&s=100&t=1566664174","introduction":"全幼儿园最可爱的小朋友","educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":"","phoneNo":null,"editable":true,"partnerId":236,"partnerIdCreateTime":1596529271,"partnerIdPoped":true},"editTime":1598338218,"state":1,"versionCount":2,"upNum":3,"downNum":0,"pics":[{"originalUrl":"https://web.archive.org/web/20221028212529/https://img04.sogoucdn.com/app/a/200698/sogou_science_2329?w=280&h=186&titlename=%E7%94%A8%E4%BA%9A%E7%94%B2%E8%93%9D%E6%9F%93%E8%89%B2%E7%9A%84%E4%BA%BA%E9%A2%8A%E7%BB%86%E8%83%9E","url":"https://web.archive.org/web/20221028212529/https://img04.sogoucdn.com/app/a/200698/sogou_science_2329","rw":280,"rh":186,"title":"用亚甲蓝染色的人颊细胞","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/app/a/200698/sogou_science_2333?h=62&titlename=&w=600","url":"https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/app/a/200698/sogou_science_2333","rw":600,"rh":62,"title":"","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/app/a/200698/sogou_science_4388?w=300&h=164&titlename=%E4%BA%9A%E7%94%B2%E5%9F%BA%E8%93%9D%E7%9A%84%E5%90%B8%E6%94%B6%E5%85%89%E8%B0%B1%EF%BC%8C%E4%BB%A5%E6%91%A9%E5%B0%94%E6%B6%88%E5%85%89%E7%B3%BB%E6%95%B0%EF%BC%88%E4%BB%A510%E4%B8%BA%E5%BA%95%E7%9A%84%E5%AF%B9%E6%95%B0%EF%BC%89%E8%A1%A8%E7%A4%BA%E3%80%82%E5%9C%A8%E8%AF%A5%E6%95%B0%E6%8D%AE%E9%9B%86%E4%B8%AD%EF%BC%8C%E5%BD%93665%20nm%E7%9A%84%E5%85%89%E9%80%9A%E8%BF%871%20cm%E7%9A%8410%20mmol%E4%BA%9A%E7%94%B2%E5%9F%BA%E8%93%9D%E6%BA%B6%E6%B6%B2%E6%97%B6%EF%BC%8C%E8%A7%82%E5%AF%9F%E5%88%B0%E5%B3%B0%E5%80%BC%E5%90%B8%E5%85%89%E5%BA%A6%E4%B8%BA1.7%EF%BC%88%E5%8D%B398%25%E7%9A%84%E9%80%8F%E5%B0%84%E5%85%89%E8%A2%AB%E5%90%B8%E6%94%B6%EF%BC%89%E3%80%82","url":"https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/app/a/200698/sogou_science_4388","rw":300,"rh":164,"title":"亚甲基蓝的吸收光谱，以摩尔消光系数（以10为底的对数）表示。在该数据集中，当665 nm的光通过1 cm的10 mmol亚甲基蓝溶液时，观察到峰值吸光度为1.7（即98%的透射光被吸收）。","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212529/https://img02.sogoucdn.com/app/a/200698/sogou_science_4389?w=300&h=400&titlename=%E8%A3%85%E6%9C%89%E4%BA%9A%E7%94%B2%E5%9F%BA%E8%93%9D%E6%BA%B6%E6%B6%B2%E7%9A%84%E5%AE%B9%E9%87%8F%E7%93%B6","url":"https://web.archive.org/web/20221028212529/https://img02.sogoucdn.com/app/a/200698/sogou_science_4389","rw":300,"rh":400,"title":"装有亚甲基蓝溶液的容量瓶","alt":null,"width":0,"height":0}],"catalogs":[{"level":1,"title":"医疗用途","paragraphId":"14994944309592581","subCatalogs":[{"level":2,"title":"高铁血红蛋白血症","paragraphId":"14994944309592581","subCatalogs":null},{"level":2,"title":"与光结合","paragraphId":"14994944309592581","subCatalogs":null},{"level":2,"title":"尿路感染","paragraphId":"14994944309592581","subCatalogs":null},{"level":2,"title":"氰化物中毒","paragraphId":"14994944309592581","subCatalogs":null},{"level":2,"title":"染料或着色剂","paragraphId":"14994944309592581","subCatalogs":null},{"level":2,"title":"安慰剂","paragraphId":"14994944309592581","subCatalogs":null},{"level":2,"title":"异环磷酰胺毒性","paragraphId":"14994944309592581","subCatalogs":null},{"level":2,"title":"休克","paragraphId":"14994944309592581","subCatalogs":null}]},{"level":1,"title":"副作用","paragraphId":"14994944326369805","subCatalogs":null},{"level":1,"title":"化学","paragraphId":"14994944326369806","subCatalogs":[{"level":2,"title":"制备","paragraphId":"14994944326369806","subCatalogs":null},{"level":2,"title":"光吸收特性","paragraphId":"14994944326369806","subCatalogs":null}]},{"level":1,"title":"其他用途","paragraphId":"14994944326369807","subCatalogs":[{"level":2,"title":"氧化还原指示剂","paragraphId":"14994944326369807","subCatalogs":null},{"level":2,"title":"过氧化物发生器","paragraphId":"14994944326369807","subCatalogs":null},{"level":2,"title":"硫化物分析","paragraphId":"14994944326369807","subCatalogs":null},{"level":2,"title":"水测试","paragraphId":"14994944326369807","subCatalogs":null},{"level":2,"title":"细集料亚甲蓝值","paragraphId":"14994944326369807","subCatalogs":null},{"level":2,"title":"生物染色","paragraphId":"14994944326369807","subCatalogs":null},{"level":2,"title":"水产养殖","paragraphId":"14994944326369807","subCatalogs":null}]},{"level":1,"title":"历史","paragraphId":"14994944326369808","subCatalogs":null},{"level":1,"title":"名称","paragraphId":"14994944326369809","subCatalogs":null},{"level":1,"title":"研究","paragraphId":"14994944343147014","subCatalogs":[{"level":2,"title":"疟疾","paragraphId":"14994944343147014","subCatalogs":null},{"level":2,"title":"阿尔茨海默氏症","paragraphId":"14994944343147014","subCatalogs":null},{"level":2,"title":"双相情感障碍","paragraphId":"14994944343147014","subCatalogs":null},{"level":2,"title":"病毒","paragraphId":"14994944343147014","subCatalogs":null}]},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"14994944309592581","title":"医疗用途","versionId":"52080200808188166","lemmaId":10103,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598338218,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p></p><h3>高铁血红蛋白血症</h3><p></p><p>亚甲蓝被用作治疗高铁血红蛋白血症的药物。病症可能是由于摄入某些药物、毒素或蚕豆引起的。<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup> 正常情况下，通过NADH或NADPH依赖的高铁血红蛋白还原酶，高铁血红蛋白被还原为血红蛋白。当大量高铁血红蛋白继发于毒素时，高铁血红蛋白还原酶不堪重负。亚甲蓝作为解毒剂静脉注射时，其本身首先被还原成无色亚甲蓝，然后将血红素从高铁血红蛋白还原成血红蛋白。亚甲蓝可以将高铁血红蛋白的半衰期从几小时缩短到几分钟。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> 然而，在高剂量下，亚甲蓝实际上会诱发高铁血红蛋白血症，逆转这一途径。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup> </p><p></p><h3>与光结合</h3><p></p><p>亚甲蓝与光结合已被用于治疗耐药斑银屑病。<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup> </p><p></p><h3>尿路感染</h3><p></p><p>亚甲蓝是一种经常使用的尿液止痛剂/抗感染剂/解痉剂的成分，称为“Prosed DS”，这是一种药物组合，也含有水杨酸苯酯、苯甲酸、硫酸天仙子胺和次甲基胺(又名六亚甲基四胺，注意：不要与“甲胺”混淆)。<sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup> </p><p></p><h3>氰化物中毒</h3><p></p><p>由于其还原电位与氧的还原电位相似，并且可以被电子传输链的成分还原，因此大剂量亚甲蓝有时被用作氰化钾中毒的解毒剂。虽然在1926年隆德大学的博·萨赫林（Bo Sahlin）首先证明了这一点，但该方法是1933年由旧金山的马蒂尔达·莫尔登豪尔·布鲁克斯博士（Dr. Matilda Moldenhauer Brooks ）首次成功检验。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup><sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup> </p><p></p><h3>染料或着色剂</h3><p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"186\" img_width=\"280\" titlename=\"用亚甲蓝染色的人颊细胞\" data-src=\"https://img04.sogoucdn.com/app/a/200698/sogou_science_2329\"> </p><p>亚甲蓝在内窥镜息肉切除术中用作盐水或肾上腺素的辅助物，并用于注射到待切除息肉周围的粘膜下层。这样可以在息肉切除后识别粘膜下层组织平面，这有助于确定是否需要切除更多组织，或者是否存在穿孔的高风险。亚甲蓝也被用作染色内窥镜检查中的染料，并被喷洒到胃肠道粘膜上，以识别发育异常或癌前病变。通过静脉注射的亚甲蓝很容易释放到尿液中，因此可用于检查泌尿道是否有渗漏或瘘管。</p><p>在诸如前哨淋巴结切除手术中，亚甲蓝可用于目视追踪受试组织的淋巴引流。同样，在整形外科手术中，亚甲蓝被添加到骨水泥中，用于区分天然骨和骨水泥。此外，亚甲蓝能够加速骨水泥的硬化速度，提高骨水泥的有效应用速度。亚甲蓝在许多医疗器械中被用作可视化/定向的辅助工具，包括外科手术密封膜，组织贴片。在瘘管和藏毛窦中，它被用来识别需要完全切除的管道。</p><p>当亚甲蓝被“多色化”(在溶液中氧化或通过真菌代谢而达到“成熟”转态，<sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup> 正如罗曼诺夫斯基（D.L.Romanowsky）博士在19世纪90年代的论文中所指出那样），它被连续脱甲基并形成所有的三甲基、二甲基、单甲基和非甲基中间体，分别对应天青A、天青B、天青C及硫堇。<sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup> 这是罗曼诺夫斯基-吉姆萨效应光谱中嗜碱性部分的基础。如果只使用合成的天青B和曙红Y，它可以作为标准的吉姆萨染色剂；但是，如果没有亚甲蓝，正常的中性粒细胞粒往往会过度染色，看起来像有毒细胞粒。另一方面，如果使用亚甲蓝，可能有助于呈现中性粒细胞颗粒的正常外观，也能增强核仁和多色性红细胞（网织红细胞）的染色。<sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup> </p><p>亚甲蓝的一个传统应用是对神经纤维进行活体或超活体染色，这种效果是保罗·埃尔利希（Paul Ehrlich ）在1887年首次描述的。<sup><a href=\"#quote_15\" class=\"kx_ref\">[15]</a></sup> 将稀释的染料溶液注射到组织中，或者涂在新鲜去除的小片上。选择性蓝色随着在空气（氧气）中暴露而显影，可以通过将染色样品浸入钼酸铵水溶液中固定下来。活性亚甲蓝以前常用于检查肌肉、皮肤和内脏的神经分布。<sup><a href=\"#quote_16\" class=\"kx_ref\">[16]</a></sup><sup><a href=\"#quote_17\" class=\"kx_ref\">[17]</a></sup><sup><a href=\"#quote_18\" class=\"kx_ref\">[18]</a></sup> 选择性染料吸收的机制还不完全清楚；哇巴因是一种抑制细胞膜钠/钾三磷酸腺苷酶（Na/K-ATPase）的药物，其可以抑制皮肤神经纤维的活体染色。<sup><a href=\"#quote_19\" class=\"kx_ref\">[19]</a></sup> </p><p></p><h3>安慰剂</h3><p></p><p>亚甲蓝被用作安慰剂；医生会告诉病人，希望他们的尿液变色，并把这看作是他们病情好转的标志。<sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup> 不利的一面是，该副作用使得亚甲蓝在传统安慰剂对照临床研究中难以测试。<sup><a href=\"#quote_21\" class=\"kx_ref\">[21]</a></sup> </p><p></p><h3>异环磷酰胺毒性</h3><p></p><p>亚甲蓝的另一个用途是治疗异环磷酰胺的神经毒性。亚甲蓝在1994年首次被报道用于异环磷酰胺神经精神毒性的治疗和预防。异环磷酰胺的有毒代谢物氯乙醛（CAA）能破坏线粒体呼吸链，导致烟酰胺腺嘌呤二核苷酸氢（NADH）的积累。亚甲蓝作为另一种替代电子受体，逆转NADH对肝脏糖异生的抑制作用，同时还能抑制氯乙胺转化为氯乙醛，并抑制多种胺氧化酶活性，防止CAA的形成。<sup><a href=\"#quote_22\" class=\"kx_ref\">[22]</a></sup> 治疗异环磷酰胺神经毒性的亚甲蓝剂量的变化取决于它在异环磷酰胺输注中作为佐剂的用途，而不是用于逆转在异环磷酰胺输注完成后出现的精神症状。报告建议，每天最多给药亚甲蓝六剂，可在10分钟至几天内改善症状。<sup><a href=\"#quote_23\" class=\"kx_ref\">[23]</a></sup> 另外，有人建议在异环磷酰胺治疗期间，对有异环磷酰胺神经精神毒性病史的人，每隔6小时静脉注射亚甲蓝进行预防。<sup><a href=\"#quote_24\" class=\"kx_ref\">[24]</a></sup> 推荐在使用异环磷酰胺开始的前一天预防性施用亚甲蓝，并在异环磷酰胺化疗期间每天施用三次，以降低异环磷酰胺神经毒性的发生可能性。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup> </p><p></p><h3>休克</h3><p></p><p>它也被用于感染性休克和过敏反应。<sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup><sup><a href=\"#quote_27\" class=\"kx_ref\">[27]</a></sup> </p><p>亚甲蓝会持续增加血管麻痹综合征（再分布性休克）患者的血压，但并未显示出可改善向组织输送氧气的效率或降低死亡率。<sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup><sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup><sup><a href=\"#quote_30\" class=\"kx_ref\">[30]</a></sup><sup><a href=\"#quote_31\" class=\"kx_ref\">[31]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028212529/https://img04.sogoucdn.com/app/a/200698/sogou_science_2329?w=280&h=186&titlename=%E7%94%A8%E4%BA%9A%E7%94%B2%E8%93%9D%E6%9F%93%E8%89%B2%E7%9A%84%E4%BA%BA%E9%A2%8A%E7%BB%86%E8%83%9E","url":"https://web.archive.org/web/20221028212529/https://img04.sogoucdn.com/app/a/200698/sogou_science_2329","rw":280,"rh":186,"title":"用亚甲蓝染色的人颊细胞","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14994944326369805","title":"副作用","versionId":"52080200808188167","lemmaId":10103,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598338218,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>\n <table class=\"wikitable\">\n  <tbody>\n   <tr>\n    <th>心血管</th>\n    <th>中枢神经系统</th>\n    <th>皮肤</th>\n    <th>胃肠</th>\n    <th>泌尿生殖系统</th>\n    <th>血液</th>\n   </tr>\n   <tr>\n    <td>• 高血压<br>• 心前区痛</td>\n    <td>• 头晕<br>• 精神混乱<br>• 头痛<br>• 发烧</td>\n    <td>• 皮肤染色<br>• 注射部位坏死</td>\n    <td>• 粪便变色<br>• 恶心<br>• 呕吐<br>• 腹痛</td>\n    <td>• 尿液变色（剂量超过80克）<br>• 膀胱刺激</td>\n    <td>• 贫血</td>\n   </tr>\n  </tbody>\n </table></p><p><sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup><sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup> </p><p>亚甲蓝是单胺氧化酶抑制剂（MAOI），<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> 当以超过5毫克/千克的剂量静脉注射时，如果其与任何选择性血清素再摄取抑制剂（SSRIs）或其他血清素再摄取抑制剂（例如度洛西汀、西布曲明、文拉法辛、氯米帕明、丙咪嗪）联用，可能会导致严重血清素毒性或血清素综合征。<sup><a href=\"#quote_35\" class=\"kx_ref\">[35]</a></sup> </p><p>它会引发G6PD（favism）酶缺乏症携带者的溶血性贫血。</p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994944326369806","title":"化学","versionId":"52080200808188168","lemmaId":10103,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598338218,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>亚甲蓝是吩噻嗪的缩甲醛衍生物。这是一种深绿色粉末，能在水中产生蓝色溶液。其水合物中，每单位亚甲蓝含有3分子水。亚甲基蓝在25℃（77℉）的水中的pH为3（10g/l）。</p><p></p><h3>制备</h3><p></p><p>该化合物通过在硫代硫酸钠存在下氧化二甲基-4-苯二胺制备：<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup> </p><p>\n </p><dl>\n  <dd>\n   <img alt=\"Synthesis of methylene blue.png\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"62\" img_width=\"600\" titlename=\"\" data-src=\"https://img03.sogoucdn.com/app/a/200698/sogou_science_2333\"> \n  </dd>\n </dl><p></p><p></p><h3>光吸收特性</h3><p></p><p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"164\" img_width=\"300\" titlename=\"亚甲基蓝的吸收光谱，以摩尔消光系数（以10为底的对数）表示。在该数据集中，当665 nm的光通过1 cm的10 mmol亚甲基蓝溶液时，观察到峰值吸光度为1.7（即98%的透射光被吸收）。\" data-src=\"https://img03.sogoucdn.com/app/a/200698/sogou_science_4388\"> </p><p>最大吸收波段大约为670纳米。吸收的具体细节取决于许多因素，包括质子化、对其他材料的吸附和异染性——这是一种根据浓度和其他相互作用形成二聚体和高阶聚集体：<sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup> </p><p>\n </p><table class=\"wikitable\">\n  <tbody>\n   <tr>\n    <th>种类</th>\n    <th>吸收峰</th>\n    <th>消光系数 (dm<sup>3</sup>/mole·cm)</th>\n   </tr>\n   <tr>\n    <td>MB<sup>+</sup>(溶液)</td>\n    <td>664</td>\n    <td>95000</td>\n   </tr>\n   <tr>\n    <td>MBH<sub>2</sub><sup>+</sup> (溶液)</td>\n    <td>741</td>\n    <td>76000</td>\n   </tr>\n   <tr>\n    <td>(MB<sup>+</sup>)<sub>2</sub> (溶液)</td>\n    <td>605</td>\n    <td>132000</td>\n   </tr>\n   <tr>\n    <td>(MB<sup>+</sup>)<sub>3</sub> (溶液)</td>\n    <td>580</td>\n    <td>110000</td>\n   </tr>\n   <tr>\n    <td>MB<sup>+</sup> (吸附在粘土上)</td>\n    <td>673</td>\n    <td>116000</td>\n   </tr>\n   <tr>\n    <td>MBH<sub>2</sub><sup>+</sup> (吸附在粘土上)</td>\n    <td>763</td>\n    <td>86000</td>\n   </tr>\n   <tr>\n    <td>(MB<sup>+</sup>)<sub>2</sub> (吸附在粘土上)</td>\n    <td>596</td>\n    <td>80000</td>\n   </tr>\n   <tr>\n    <td>(MB<sup>+</sup>)<sub>3</sub> (吸附在粘土上)</td>\n    <td>570</td>\n    <td>114000</td>\n   </tr>\n  </tbody>\n </table><p></p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/app/a/200698/sogou_science_2333?h=62&titlename=&w=600","url":"https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/app/a/200698/sogou_science_2333","rw":600,"rh":62,"title":"","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/app/a/200698/sogou_science_4388?w=300&h=164&titlename=%E4%BA%9A%E7%94%B2%E5%9F%BA%E8%93%9D%E7%9A%84%E5%90%B8%E6%94%B6%E5%85%89%E8%B0%B1%EF%BC%8C%E4%BB%A5%E6%91%A9%E5%B0%94%E6%B6%88%E5%85%89%E7%B3%BB%E6%95%B0%EF%BC%88%E4%BB%A510%E4%B8%BA%E5%BA%95%E7%9A%84%E5%AF%B9%E6%95%B0%EF%BC%89%E8%A1%A8%E7%A4%BA%E3%80%82%E5%9C%A8%E8%AF%A5%E6%95%B0%E6%8D%AE%E9%9B%86%E4%B8%AD%EF%BC%8C%E5%BD%93665%20nm%E7%9A%84%E5%85%89%E9%80%9A%E8%BF%871%20cm%E7%9A%8410%20mmol%E4%BA%9A%E7%94%B2%E5%9F%BA%E8%93%9D%E6%BA%B6%E6%B6%B2%E6%97%B6%EF%BC%8C%E8%A7%82%E5%AF%9F%E5%88%B0%E5%B3%B0%E5%80%BC%E5%90%B8%E5%85%89%E5%BA%A6%E4%B8%BA1.7%EF%BC%88%E5%8D%B398%25%E7%9A%84%E9%80%8F%E5%B0%84%E5%85%89%E8%A2%AB%E5%90%B8%E6%94%B6%EF%BC%89%E3%80%82","url":"https://web.archive.org/web/20221028212529/https://img03.sogoucdn.com/app/a/200698/sogou_science_4388","rw":300,"rh":164,"title":"亚甲基蓝的吸收光谱，以摩尔消光系数（以10为底的对数）表示。在该数据集中，当665 nm的光通过1 cm的10 mmol亚甲基蓝溶液时，观察到峰值吸光度为1.7（即98%的透射光被吸收）。","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14994944326369807","title":"其他用途","versionId":"52080200808188169","lemmaId":10103,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598338218,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><img alt=\"\" class=\"fileimage kx_img ed_imgfloat_right\" img_height=\"400\" img_width=\"300\" titlename=\"装有亚甲基蓝溶液的容量瓶\" data-src=\"https://img02.sogoucdn.com/app/a/200698/sogou_science_4389\"> </p><p></p><h3>氧化还原指示剂</h3><p></p><p>亚甲蓝被广泛地用作分析化学中的氧化还原指示剂。在氧化环境中，这种物质的溶液是蓝色的，但是如果暴露在还原剂中，溶液会变成无色的。氧化还原性质可以在普通化学的化学动力学的经典演示“蓝瓶”实验中看到。通常，溶液由葡萄糖（右旋糖）、亚甲蓝和氢氧化钠组成。摇动瓶子时，氧气氧化亚甲蓝，溶液变成蓝色。葡萄糖会逐渐将亚甲蓝还原成无色的还原型。因此，当溶解的葡萄糖被完全消耗时，溶液将再次变成蓝色。氧化还原中点电位E0’为+0.011毫伏。<sup><a href=\"#quote_38\" class=\"kx_ref\">[38]</a></sup> </p><p></p><h3>过氧化物发生器</h3><p></p><p>亚甲蓝也是一种光敏剂，用于在暴露于氧气和光线时产生单线态氧。 它被用于通过狄尔斯-阿尔德（Diels-Alder）反应制备有机过氧化物，该反应在正常大气中三线态氧环境下是自旋禁止的。</p><p></p><h3>硫化物分析</h3><p></p><p>硫化氢与二甲基对苯二胺和铁（III）在pH0.4–0.7条件下反应后形成亚甲蓝，通过分光光度法测定硫化物浓度范围为0.020至1.50mg/l（20 ppb至1.5 ppm）。该测试非常灵敏，试剂与溶解的H<sub>2</sub>S接触时产生的蓝色稳定60 分钟。即用型试剂盒如光谱定量硫化物测试方便了例行分析。<sup><a href=\"#quote_39\" class=\"kx_ref\">[39]</a></sup> 亚甲蓝硫化物试验是土壤微生物学中常用的一种快速检测水中硫酸盐还原菌（SRB）代谢活性的简便方法。应该注意到在该试验中，亚甲蓝是反应的产物，而不是试剂。</p><p>向含硫化物的溶液中加入强还原剂，如抗坏血酸，有时用于防止硫化物在大气氧中氧化。尽管用离子选择性电极测定硫化物也确实是一个很好的预防措施，但如果新形成的亚甲基蓝也被还原，则可能会妨碍蓝色的形成，如上文氧化还原指示剂一节所述。</p><p></p><h3>水测试</h3><p></p><p>在含有氯仿的酸化亚甲蓝水溶液中的显色反应可以检测水样中的阴离子表面活性剂。这种试验被称为MBAS试验（亚甲蓝活性物质试验）。</p><p>然而，MBAS分析不能区分特定的表面活性剂。阴离子表面活性剂的一些实例是羧酸盐、磷酸盐、硫酸盐和磺酸盐。</p><p></p><h3>细集料亚甲蓝值</h3><p></p><p>亚甲蓝值反映了集料样品中粘土矿物的数量。亚甲蓝溶液被连续加入到正在水中搅拌的细集料中。可用滤纸上的染色试验来检查游离染料溶液的存在。<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup> </p><p></p><h3>生物染色</h3><p></p><p>在生物学中，亚甲蓝被用作许多不同染色程序的染料，例如Wright染色和Jenner染色。由于它是一种临时染色技术，亚甲蓝也可用于在显微镜下或凝胶中检查核糖核酸（RNA）或脱氧核糖核酸（DNA）：例如，亚甲蓝溶液可用于在northern印迹中对杂交膜上的核糖核酸进行染色，以验证核酸的存在量。虽然亚甲蓝不如溴化乙锭敏感，但毒性较低，并且不嵌入核酸链，因此避免了对杂交膜上保留的核酸或杂交过程本身的干扰。</p><p>它也可以用作确定真核细胞如酵母存活或者死亡的指示物。亚甲蓝在活细胞中被还原，使其避免染色。然而死细胞不能还原被氧化的亚甲蓝，细胞被染成蓝色。亚甲蓝会干扰酵母的呼吸，因为它会吸收在此过程中产生的氢离子。</p><p></p><h3>水产养殖</h3><p></p><p>亚甲蓝被水产养殖从业者和热带鱼爱好者用作真菌感染的治疗手段。虽然孔雀石绿和甲醛的组合对寄生的原生动物多子小瓜虫（ich）更有效，但亚甲蓝也能有效治疗感染ich的鱼。它通常用于保护新产的鱼卵免受真菌或细菌的感染。当爱好者想要人工孵化鱼卵时，这很有用。亚甲蓝在作为“药浴”的一部分用于治疗氨、亚硝酸盐和氰化物中毒以及作为“第一反应”用于受伤或患病鱼的局部和内部治疗时也非常有效。<sup><a href=\"#quote_41\" class=\"kx_ref\">[41]</a></sup> </p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028212529/https://img02.sogoucdn.com/app/a/200698/sogou_science_4389?w=300&h=400&titlename=%E8%A3%85%E6%9C%89%E4%BA%9A%E7%94%B2%E5%9F%BA%E8%93%9D%E6%BA%B6%E6%B6%B2%E7%9A%84%E5%AE%B9%E9%87%8F%E7%93%B6","url":"https://web.archive.org/web/20221028212529/https://img02.sogoucdn.com/app/a/200698/sogou_science_4389","rw":300,"rh":400,"title":"装有亚甲基蓝溶液的容量瓶","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"14994944326369808","title":"历史","versionId":"52080200808188170","lemmaId":10103,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598338218,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>亚甲蓝被描述为“第一种用于医药的全合成药物”。亚甲蓝最初是由德国化学家海因里希·卡罗（Heinrich Caro）在1876年制备的。<sup><a href=\"#quote_42\" class=\"kx_ref\">[42]</a></sup> </p><p>保罗·古特曼（Paul Guttmann）和保罗·埃尔利希（Paul Ehrlich）在1891年率先将它用于治疗疟疾。在第一次世界大战前的这段时间里，像埃利希这样的研究人员认为，药物和染料的作用方式是一样的，优先染色病原体，并可能对它们造成伤害。各种药物的作用方式实际上是改变病原体的细胞膜，所以这个理论虽然远未完成，但部分正确。亚甲蓝在第二次世界大战中被继续使用，然而士兵们并不太喜欢它，他们说：“即使在厕所，我们也看到；我们撒尿时也看到，海军蓝。” 最近恢复了这种药物的抗疟药使用。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup> 马蒂尔达·布鲁克斯（Matilda Brooks）在1933年发现它是一氧化碳中毒和氰化物中毒的解毒剂。<sup><a href=\"#quote_44\" class=\"kx_ref\">[44]</a></sup> </p><p>蓝色尿液用于监测精神病患者对药物治疗方案的依从性。从19世纪90年代至今，这引起了人们对这种药物的抗抑郁和其他精神作用的兴趣。它成为导致氯丙嗪被发现研究中的先导化合物。 </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994944326369809","title":"名称","versionId":"52080200808188171","lemmaId":10103,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598338218,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>亚甲蓝的国际非专利名称（INN）是氯化亚甲基硫堇。<sup><a href=\"#quote_45\" class=\"kx_ref\">[45]</a></sup><sup><a href=\"#quote_46\" class=\"kx_ref\">[46]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14994944343147014","title":"研究","versionId":"52080200808188172","lemmaId":10103,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":81910391,"name":"哈哈","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1598338218,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3>疟疾</h3></p><p>亚甲蓝大约在1891年被保罗·埃尔利希确定为一种可能的疟疾治疗方法。<sup><a href=\"#quote_47\" class=\"kx_ref\">[47]</a></sup> 在太平洋战争期间，它作为抗疟疾药在热带地区消失了，因为美国和盟军士兵不喜欢它的两个显著但可逆的副作用：尿液变成蓝色或绿色，巩膜（眼白）变成蓝色。最近人们对其作为抗疟疾药物的兴趣有所恢复，<sup><a href=\"#quote_48\" class=\"kx_ref\">[48]</a></sup> 特别是由于其价格低廉。一些临床试验正在进行中，试图找到一种合适的药物组合。根据对非洲儿童的研究，它似乎对疟疾有疗效，但是将亚甲蓝和氯喹结合的尝试令人失望。<sup><a href=\"#quote_48\" class=\"kx_ref\">[48]</a></sup> </p><p><h3>阿尔茨海默氏症</h3></p><p>亚甲蓝衍生物-LMTM（TauRx0237或LMT-X）的3期临床试验数据未能显示出对轻度至中度阿尔茨海默病患者的认知或功能衰退有任何益处。药物和安慰剂对疾病进程的作用是几乎相同的。<sup><a href=\"#quote_49\" class=\"kx_ref\">[49]</a></sup><sup><a href=\"#quote_50\" class=\"kx_ref\">[50]</a></sup> </p><p><h3>双相情感障碍</h3></p><p>亚甲蓝已被研究作为治疗双相情感障碍的辅助药物。<sup><a href=\"#quote_51\" class=\"kx_ref\">[51]</a></sup> </p><p><h3>病毒</h3></p><p>亚甲蓝在与艾滋病相关的卡波西肉瘤、<sup><a href=\"#quote_52\" class=\"kx_ref\">[52]</a></sup> 西尼罗河病毒、<sup><a href=\"#quote_53\" class=\"kx_ref\">[53]</a></sup> 灭活金菌黄色葡萄球<sup><a href=\"#quote_54\" class=\"kx_ref\">[54]</a></sup> 和HIV-1中被研究过。<sup><a href=\"#quote_55\" class=\"kx_ref\">[55]</a></sup> 吩噻嗪染料和光在70多年前就被认为具有杀病毒特性。<sup><a href=\"#quote_56\" class=\"kx_ref\">[56]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"book","title":"\"Methylene Blue\". The American Society of Health-System Pharmacists. Archived from the original on 10 May 2017. Retrieved 8 January 2017.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"book","title":"British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 34. ISBN 9780857111562.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"book","title":"Ahmad, Iqbal; Aqil, Farrukh (2008). New Strategies Combating Bacterial Infection (in 英语). John Wiley & Sons. p. 91. ISBN 9783527622948. Archived from the original on 2017-09-18.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"book","title":"\"WHO Model List of Essential Medicines (19th List)\" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"book","title":"\"Provayblue Prices, Coupons & Patient Assistance Programs - Drugs.com\". www.drugs.com. Archived from the original on 16 January 2017. Retrieved 12 January 2017.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"book","title":"Manual of Clinical Hematology Archived 2017-09-18 at the Wayback Machine, Joseph Mazza","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"book","title":"Brent J. (2005). Critical care toxicology: diagnosis and management of the critically poisoned patient. Elsevier Health Sciences.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"book","title":"Salah M.; Samy N.; Fadel M. (January 2009). \"Methylene blue mediated photodynamic therapy for resistant plaque psoriasis\". J. Drugs Dermatol. 8 (1): 42–9. PMID 19180895.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"book","title":"\"Prosed DS (Methenamine, Salicylate, Methylene Blue, Benzoic Acid Atropine and Hyoscyamine) Drug Information: Description, User Reviews, Drug Side Effects, Interactions - Prescribing Information at RxList\". RxList. Archived from the original on 2011-11-02.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"book","title":"Matilda Moldenhauer Brooks (1936). \"Methylene blue as an antidote for cyanide and carbon monoxide poisoning\". The Scientific Monthly. 43 (6): 585–586. Bibcode:1936SciMo..43..585M. JSTOR 16280.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"book","title":"Hanzlik, P. J. (4 February 1933). \"Methylene Blue As Antidote for Cyanide Poisoning\". JAMA. 100 (5): 357. doi:10.1001/jama.1933.02740050053028.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"book","title":"Dako Education Guide - Special Stains and H & E \" second edition Chapter 19: On Chemical Reactions and Staining Mechanisms by John A. Kiernan, Subsection What is Giemsa's stain and how does it color blood cells, bacteria and chromosomes? p172 Archived 2012-05-13 at the Wayback Machine","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"book","title":"Wilson TM (1907). \"ON THE CHEMISTRY AND STAINING PROPERTIES OF CERTAIN DERIVATIVES OF THE METHYLENE BLUE GROUP WHEN COMBINED WITH EOSIN\". J Exp Med. 9 (6): 645–70. doi:10.1084/jem.9.6.645. PMC 2124692. PMID 19867116.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":14,"type":"book","title":"Dacie and Lewis Practical Haematology 10th ed, p61","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":15,"type":"book","title":"Ehrlich, P. (1887) Biol. Centralblatt 6: 214, cited from Baker JR (1958) Principles of Biological Microtechnique (Reprinted 1970, with corrections). Methuen, London.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":16,"type":"book","title":"Wilson JG (1910) Intra vitam staining with methylene blue. Anatomical Record 4: 267-277.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":17,"type":"book","title":"Schabadasch A (1930) Untersuchungen zur Methodik der Methylenblaufarbung des vegetativen Nervensystems. Zeitschrift für Zellforschung 10: 221-243.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":18,"type":"book","title":"Zacks Zacks SI (1973) The Motor Endplate, 2nd ed. Huntington, NY: Krieger","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":19,"type":"book","title":"Kiernan JA (1974) Effects of metabolic inhibitors on vital staining with methylene blue. Histochemistry 40: 51-57.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":20,"type":"book","title":"Novella Steve. \"The ethics of deception in medicine\". Science Based Medicine. Archived from the original on 2008-01-29. Retrieved 2008-01-24.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":21,"type":"book","title":"\"Methylene blue for cognitive dysfunction in bipolar disorder\". United States National Library of Medicine. September 20, 2005. Archived from the original on January 15, 2009. Retrieved 2009-02-15.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":22,"type":"book","title":"Alici-Evcimen Y.; Breitbart W.S. (October 2007). \"Ifosfamide neuropsychiatric toxicity in patients with cancer\". Psychooncology. 16 (10): 956–960. doi:10.1002/pon.1161. PMID 17278152.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":23,"type":"book","title":"Patel P.N. (2006). \"Methylene blue for management of ifosfamide induced encephalopathy\". Annals of Pharmacotherapy. 40 (2): 266–303. doi:10.1345/aph.1G114. PMID 16391008.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":24,"type":"book","title":"Dufour C., Grill J., Sabouraud P., et al. (February 2006). \"Ifosfamide induced encephalopathy: 15 observations\". Arch. Pediatr. (in French). 13 (2): 140–145. doi:10.1016/j.arcped.2005.10.021. PMID 16364615.CS1 maint: Unrecognized language (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":25,"type":"book","title":"Aeschlimann T.; Cerny, T; Küpfer, A (1996). \"Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue\". Drug Metab. Dispos. 24 (12): 1336–1339. PMID 8971139.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":26,"type":"book","title":"Jang, DH; Nelson, LS; Hoffman, RS (September 2013). \"Methylene blue for distributive shock: a potential new use of an old antidote\". Journal of Medical Toxicology. 9 (3): 242–9. doi:10.1007/s13181-013-0298-7. PMID 23580172.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":27,"type":"book","title":"Paciullo, CA; McMahon Horner, D; Hatton, KW; Flynn, JD (July 2010). \"Methylene blue for the treatment of septic shock\". Pharmacotherapy. 30 (7): 702–15. doi:10.1592/phco.30.7.702. PMID 20575634.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":28,"type":"book","title":"Hosseinian L, Weiner M, Levin MA, Fischer GW (January 2016). \"Methylene Blue: Magic Bullet for Vasoplegia?\". Anesth. Analg. 122 (1): 194–201. doi:10.1213/ANE.0000000000001045. PMID 26678471.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":29,"type":"book","title":"Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, Boullon FJ (February 2004). \"Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery\". Ann Thorac Surg. 77 (2): 496–9. doi:10.1016/S0003-4975(03)01510-8. PMID 14759425.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":30,"type":"book","title":"\"BestBets: Is Methylene Blue of benefit in treating adult patients who develop vasoplegic syndrome during Cardiac Surgery\". Archived from the original on 2014-07-28.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":31,"type":"book","title":"Stawicki SP, Sims C, Sarani B, Grossman MD, Gracias VH (May 2008). \"Methylene blue and vasoplegia: who, when, and how?\". Mini Rev Med Chem. 8 (5): 472–90. doi:10.2174/138955708784223477. PMID 18473936.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":32,"type":"book","title":"Mokhlesi B.; Leikin J.B.; Murray P.; Corbridge T.C. (March 2003). \"Adult toxicology in critical care: Part II: specific poisonings\". Chest. 123 (3): 897–922. doi:10.1378/chest.123.3.897. PMID 12628894.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":33,"type":"book","title":"Harvey J.W.; Keitt A.S. (May 1983). \"Studies of the efficacy and potential hazards of methylene blue therapy in aniline-induced methaemoglobinaemia\". Br. J. Haematol. 54 (1): 29–41. doi:10.1111/j.1365-2141.1983.tb02064.x. PMID 6849836.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":34,"type":"book","title":"Ramsay RR; Dunford, C.; Gillman, C.K. (August 2007). \"Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction\". Br J Pharmacol. 152 (6): 946–951. doi:10.1038/sj.bjp.0707430. PMC 2078225. PMID 17721552.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":35,"type":"book","title":"Gillman P.K. (October 2006). \"Methylene blue implicated in potentially fatal serotonin toxicity\". Anaesthesia. 61 (10): 1013–4. doi:10.1111/j.1365-2044.2006.04808.x. PMID 16978328.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":36,"type":"book","title":"Horst Berneth (2012). \"Azine Dyes\". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a03_213.pub3. ISBN 978-3527306732.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":37,"type":"book","title":"J. Cenens; R. A. Schoonheydt (1988). \"Visible spectroscopy of methylene blue on hectorite, laponite B, and barasym in aqueous suspension\" (PDF). Clay and Clay Minerals. 36 (3): 214–224. Bibcode:1988CCM....36..214C. doi:10.1346/ccmn.1988.0360302. Archived (PDF) from the original on 2011-06-12.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":38,"type":"book","title":"HEWITT, LF. \"Oxidation-Reduction Potentials in Bacteriology and Biochemistry.\" Oxidation-Reduction Potentials in Bacteriology and Biochemistry. Edn 6 (1950).","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":39,"type":"book","title":"\"Analytik und Probenvorbereitung\". Archived from the original on 2007-03-15.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":40,"type":"book","title":"Construction Standard CS3:2013 – Aggregates for Concrete Archived 2014-06-02 at the Wayback Machine","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":41,"type":"book","title":"[1] Archived 2016-01-10 at the Wayback Machine","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":42,"type":"book","title":"Badische Anilin- und Sodafabrik [BASF] (Mannheim, Germany), \"Verfahren zur Darstellung blauer Farbstoffe aus Dimethylanilin und anderen tertiaren aromatischen Monaminen\" (Method for preparation of blue dyes from dimethylaniline and other tertiary aromatic monoamines), Deutsches Reich Patent no. 1886 (December 15, 1877). Available on-line at: P. Friedlaender, Fortschritte der Theerfarbenfabrikation und verwandter Industriezweige (Progress of the manufacture of coal-tar dyes and related branches of industry), volume 1 (Berlin, Germany: Julius Springer, 1888), pages 247-249. Archived 2015-03-21 at the Wayback Machine","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":43,"type":"book","title":"Coulibaly, Boubacar; Zoungrana, Augustin; Mockenhaupt, Frank P.; Schirmer, R. Heiner; Klose, Christina; Mansmann, Ulrich; Meissner, Peter E.; Müller, Olaf (2009). \"PLOS ONE\". PLoS ONE. 4 (5): e5318. Bibcode:2009PLoSO...4.5318C. doi:10.1371/journal.pone.0005318. PMC 2673582. PMID 19415120.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":44,"type":"book","title":"Brooks, Matilda Moldenhauer (1933). \"Methylene Blue As Antidote for Cyanide and Carbon Monoxide Poisoning\". JAMA. 100: 59. doi:10.1001/jama.1933.02740010061028.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":45,"type":"book","title":"Adams V.; Marley J.; McCarroll C. (November 2007). \"Prilocaine induced methaemoglobinaemia in a medically compromised patient. Was this an inevitable consequence of the dose administered?\". Br. Dent. J. 203 (10): 585–7. doi:10.1038/bdj.2007.1045. PMID 18037845.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":46,"type":"book","title":"Linz A.J.; Greenham R.K.; Fallon L.F. (May 2006). \"Methemoglobinemia: an industrial outbreak among rubber molding workers\". J. Occup. Environ. Med. 48 (5): 523–8. doi:10.1097/01.jom.0000201815.32098.99. PMID 16688009.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":47,"type":"book","title":"Guttmann, P. and Ehrlich. P. (1891) \"Über die Wirkung des Methylenblau bei Malaria\" Archived 2017-02-17 at the Wayback Machine (On the effect of methylene blue on malaria), Berliner Klinische Wochenschrift, 28 : 953-956.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":48,"type":"book","title":"Schirmer H.; Coulibaly B.; Stich A.; et al. (2003). \"Methylene blue as an antimalarial agent—past and future\". Redox Rep. 8 (5): 272–276. doi:10.1179/135100003225002899. PMID 14962363.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":49,"type":"book","title":"\"Tau Drug Flops in Study\".","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":50,"type":"book","title":"\"In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period\".","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":51,"type":"book","title":"Alda, Martin; McKinnon, Margaret; Blagdon, Ryan; Garnham, Julie; MacLellan, Susan; O'Donovan, Claire; Hajek, Tomas; Nair, Cynthia; Dursun, Serdar (2017-01-01). \"Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study\". The British Journal of Psychiatry. 210 (1): 54–60. doi:10.1192/bjp.bp.115.173930. ISSN 1472-1465. PMID 27284082.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":52,"type":"book","title":"Tardivo J.P.; Del Giglio A.; Paschoal L.H.; Baptista M.S. (August 2006). \"New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma\". Photomedical Laser Surg. 24 (4): 528–31. doi:10.1089/pho.2006.24.528. PMID 16942436.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":53,"type":"book","title":"Papin J.F.; Floyd R.A.; Dittmer D.P. (November 2005). \"Methylene blue photoinactivation abolishes West Nile virus infectivity in vivo\". Antiviral Res. 68 (2): 84–7. doi:10.1016/j.antiviral.2005.07.001. PMID 16118025.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":54,"type":"book","title":"Zolfaghari P.S.; Packer S.; Singer M.; Nair S.P.; Bennett J.; Street C.; Wilson M. (2009). \"In vivo killing of Staphylococcus aureus using a light-activated antimicrobial agent\". BMC Microbiol. 9: 27. doi:10.1186/1471-2180-9-27. PMC 2642833. PMID 19193212.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":55,"type":"book","title":"Floyd R.A.; Schneider J.E.; Dittmer D.P. (March 2004). \"Methylene blue photoinactivation of RNA viruses\". Antiviral Res. 61 (3): 141–51. doi:10.1016/j.antiviral.2003.11.004. PMID 15168794.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":56,"type":"book","title":"Wagner S.J.; Skripchenko A.; Robinette D.; Mallory D.A.; Hirayama J.; Cincotta L.; Foley J. (2000). \"The use of dimethylmethylene blue for virus photoinactivation of red cell suspensions\". Dev. Biol. (Basel). 102: 125–9. PMID 10794099.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":5505,"auditType":2,"synonyms":["Methylene blue"],"showEditTime":"2020.08.25 14:50","auditors":[{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221028212529/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true}],"hasZhishiNav":false,"auditInfos":{"0":[{"versionId":"0","auditTime":1598338305,"auditorId":5567290,"auditUser":{"uid":5567290,"name":"人间小太阳","pic":"https://web.archive.org/web/20221028212529/https://cache.soso.com/qlogo/g?b=oidb&k=4xjGfuUZbbjZEI7OAVIVEg&s=100&t=1609215301","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":250,"partnerIdCreateTime":1598322359,"partnerIdPoped":true},"auditReason":"","auditSuggest":"简单修改","auditResult":2,"auditAnnotations":null}]},"isHistory":false};</script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./103.亚甲蓝 - 搜狗科学百科_files/main_edf0f08.js.download"></script>
</body></html>